Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis
Abstract Background The high rates of the sustained virologic response 12 weeks after treatment (SVR12) in real world settings provoked the adoption of shortened courses of the costly direct-acting antivirals (DAAs) regimens. This study provides, to our knowledge, the first systematic review and met...
Saved in:
| Main Authors: | Ahmed N. Farrag, Ahmed M. Kamel |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Virology Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12985-024-02544-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
by: M. V. Mayevskaya, et al.
Published: (2015-12-01) -
Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients
by: Juferdy Kurniawan, et al.
Published: (2024-10-01) -
Predictors of response to daclatasvir in addition to sofosbuvir in hepatitis C virus-infected patients with stage 4 and 5 chronic kidney disease and patients on maintenance hemodialysis
by: Rasha Gawish, et al.
Published: (2025-01-01) -
Effectiveness of sofosbuvir-based treatments for patients with hepatitis C virus genotype 6 infection: a real-world study from East China
by: Fan-Rong Jiang, et al.
Published: (2024-11-01) -
Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
by: Takuya Matsubara, et al.
Published: (2025-01-01)